API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.ema.europa.eu/en/documents/overview/lytgobi-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/lytgobi-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/european-commission-grants-conditional-marketing-authorization-for-taihos-lytgobi-tablets-for-the-treatment-of-adults-with-cholangiocarcinoma-301869543.html
https://www.prnewswire.com/news-releases/chmp-issues-positive-opinion-for-futibatinib-for-the-treatment-of-adults-with-cholangiocarcinoma-301808851.html
https://www.prnewswire.com/news-releases/taiho-oncology-announces-publication-in-the-new-england-journal-of-medicine-of-pivotal-data-for-futibatinib-in-previously-treated-patients-with-metastatic-intrahepatic-cholangiocarcinoma-301725166.html
https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come
https://endpts.com/fda-greenlights-otsuka-subsidiarys-bile-duct-cancer-drug/
https://www.prnewswire.com/news-releases/taiho-oncology-to-present-data-on-futibatinib-tas-120-at-the-aacr-annual-meeting-2020-301069483.html